Are you ready to dive into the future of medicine and the revolutionary advancements being made with artificial intelligence? In this episode, I sit down with Alex Zhavoronkov, the founder and CEO of Insilico Medicine, a global company focused on the discovery of novel therapeutics utilizing cutting-edge technology in healthcare.
From longevity research to anti-aging treatments, Alex shares his expertise on the
most impactful field of our time, discussing his work in protein target
discovery and the design of small molecule drugs using generative AI.
But it doesn't stop there. Alex also shares insights into the development of aging
clocks, biomarkers of aging, and precision medicine. Discover how generative AI
is transforming the pharmaceutical industry, improving clinical trials, and
providing a revolutionary new approach to drug discovery methods.
Don't miss out on this incredible opportunity to learn from one of the leading
experts in AI and healthcare innovation. Tune in now and join us on this
fascinating journey into the future of medicine.
💡 LINKS TO MORE CONTENT
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Watch on Youtube
Check out the organizations that make the podcast possible
📖 Memorable quotes:
(10:50) “Insilico Medicine synthesized and tested the first AI generated drug in 2017.”
(23:09) “Generative AI in Drug Discovery and Drug Development has the potential to improve the probability of success by 50%”
(24:00) “Generating 11 preclinical candidates in 2.5 years - is a pretty cool number.”
(29:48) “We developed a clinical candidate in 18 months at a 3 million dollar cost with the help of AI. The traditional route takes 2 years at about 400 million expeonses.”
(01:08:48) “Generative AI will transform our lives beyond recognition in every way.”
(02:00) Introduction to Alex Zhavoronkov at World Government Summit 2023
(03:00) About World Government Summit 2023
(04:20) Alex's longevity research at Insilico Medicine
(08:20) Accelerating drug discovery with AI
(13:00) AI in synthetic biologic data
(15:00) Generative AI in reducing cost and increasing output
(23:30) Generative AI in increasing probability of success
(25:00) Why traditional drug R&D takes over 10 years and 2 billion 2010 dollars
(28:45) AI-driven drug discovery at Insilico Medicine
(30:30) Insilico Medicine's pipeline and case study
(38:09) Regulators' perception of AI in drug development
(45:26) Generative AI inThe Physician Syndicate: Angel Investing | Venture Capital | Startups | Personal Finance
Listen on: Apple Podcasts SpotifyStreamlined Media
Do you want to support the podcast team?
Join the LSG2G Newsletter as a paying member: Link